Introduction
Childhood epilepsy is a common neurological condition associated with a considerable medical and psychosocial burden. In up to one-third of children, medical therapy is ineffective at decreasing seizure frequency. This sizeable group of children represents an exquisitely vulnerable patient population, because uncontrolled seizures have been linked to poor developmental, cognitive and behavioral outcomes. 1, 2 Furthermore, a longer duration of epilepsy is associated with a lesser likelihood of future seizure-freedom, suggesting that early treatment is essential to prevent chronic epilepsy, which can significantly impair qualityof-life in children. 3, 4 It is not surprising therefore, that increasingly aggressive surgical strategies have become more commonplace in the treatment of medically-refractory childhood epilepsy. Indeed, we have previously reviewed numerous ethical justifications for surgical intervention, even in children with relatively modest expected improvements or severe developmental delay. 5 In contrast to adults, children often present with extensive extra-temporal and multi-lobar epileptic foci. Therefore, the accurate mapping and subsequent resection of the epileptogenic zone -the minimum brain areas required for removal to achieve seizure freedom -are of utmost importance. At present there is no recognized gold standard for the determination of the epileptogenic zone. The use of ictal and interictal high frequency oscillations (HFOs) as a biomarker of epileptogenicity to guide neocortical resections has gained increasing popularity. [6] [7] [8] [9] HFOs, which are acquired by applying frequency analysis to electroencephalographic recordings from implanted subdural electrodes, Purpose: Resective surgical strategies are increasingly applied to treat medically-intractable epilepsy in children as uncontrolled seizures are associated with poor cognitive, developmental and behavioral outcomes. Innovative surgical strategies are, however, needed to improve outcomes and minimize the morbidity of such procedures. Method: The current article utilizes an axiological approach to explore and highlight ethical issues in the use of high frequency oscillations (HFOs) to guide surgical resections in children with medicallyintractable epilepsy. We frame our discussion in the context of the broader challenges in the application of surgical innovation to patient care. Results: Despite a paucity of knowledge regarding their pathogenesis, limited evidence suggests the use of HFOs as biomarkers of epileptogenicity in resective procedures can improve seizure outcome. Clinicians must therefore weigh deficiencies in knowledge against the limited evidence supporting the utility of HFOs and make ethical decisions for the treatment of individual patients. Important ethical considerations for clinicians include the extent of deviation from established practice, the extent of evidence required to establish clinical validity, and the impact of technique implementation on equitable distribution of healthcare.
Conclusion:
The use of HFO signatures to guide neocortical resections represents a novel approach for the treatment of epilepsy. It is hoped that the issues discussed herein will contribute to and advance meaningful dialog on the ethical application of this surgical innovation to the treatment of a very vulnerable patient population. ß 2012 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
are thought to represent the synchronous firing of abnormally bursting principal cells localized to a discrete neuronal cluster. 10 It has been shown in animal models that the presence of electroencephalographic HFOs precedes clinical seizures following an epileptogenic injury 11 and that the number of electrodes expressing HFOs is associated with higher seizure frequency. 12 Furthermore, small retrospective series have demonstrated that resection of cortical regions expressing HFOs is associated with improved post-surgical outcomes. 8, 9, 13, 14 Our institution has previously described the use of fast-ripple band power as a marker of epileptogenicity to guide neocortical resections, using multiple band frequency analysis. 8, 9 While a confluence of low-level evidence suggests that HFOs may be a useful marker to guide resective epilepsy surgery, important unanswered questions temper the enthusiasm for their broad application to patient care. Firstly, the physiological mechanisms underlying the generation of epileptic HFOs are asof-yet unknown and furthermore, normal cortex in human and animal models has been shown to exhibit oscillations in the HFO range. 15, 16 Additionally, the fundamental neuronal mechanisms that underlie the propagation, synchronization, coalescence and expansion of HFOs leading to the ictus have yet to be elucidated. Finally, long-term follow-up data are lacking, which poses a significant challenge given that recurrence of seizures may be delayed by many years following surgical resection. 17 The challenge for clinicians is, therefore, to balance low-level population-based evidence supporting the use of HFOs to guide surgical resection with an incomplete understanding of the pathophysiology of HFOs and ultimately make ethical decisions for individual patients. This challenge is furthermore augmented by the invasive and irreversible nature of resective surgery. At present, there are no accepted guidelines or frameworks in place to guide the surgeon in evaluating surgical innovations and ethically applying them to patient care. The current article presents germane ethical issues for clinicians regarding the use of HFOs to guide surgical resection within the broader context of challenges in applying surgical innovations to patient care. It is hoped that the considerations presented herein will facilitate and advance meaningful dialog on the utility of this emerging tool in the armamentarium of epileptologists and neurosurgeons in the management of drug-resistant epilepsy.
Methods
We applied an axiological approach to highlight ethical issues in the use of HFOs to guide resective epilepsy surgery, whereby a series of ethically-relevant questions is posed to underscore key issues. This method is described in-depth by Hofmann 18 and has been effectively applied to the ethical analyses of other surgical innovations, such as bariatric surgery. 19 Axiological ethics is based on the principle that judgments should be based on the value of an object or process. Such determinations may encompass its associated actions, motives and consequences. The approach is defined by a set of interrelated moral questions that may be relevant in the assessment of health technology. 18 These questions are grouped into five broad categories, namely related to (a) moral issues; (b) the stakeholders of the surgical innovation; (c) the technology itself; (d) methodological choices; and (e) technology assessment.
In the current axiological study, we concatenated multiple categories into three overarching questions to highlight relevant ethical considerations. The questions are neither exhaustive nor exclusive and their objective is neither to develop recommendations nor to build a useable framework; rather, their purpose is to clearly and methodologically highlight selected ethical considerations to advance dialog on the ethical use of HFOs to guide surgical resections. 18 
To what extent does the use of HFOs to guide resective epilepsy surgery deviate from established practices?
Partially created in response to the unethical research practices of the Tuskegee Syphilis Study , the Belmont report outlines ethical criteria for the conduct of human research. Therein, innovation is defined as ''practice that departs significantly from the standard or accepted''. 20 McKneally further distinguishes between innovation and research by proposing that in contrast to the latter, the former is characterized by evolving techniques, outcome measures and patient selection. 21 The extent to which a novel surgical practice requires regulation and careful oversight of its broad application to patient care is directly related to the degree to which it deviates from established practices. The senior author (M.B.) has previously proposed a classification system to stratify surgical (and specifically neurosurgical) innovations based on their need for such regulation. 22 In Table   1 , we present a modified version of this classification system with examples of surgical innovations in epilepsy. In keeping with this system, the inclusion of HFO data to guide resective epilepsy procedures can be considered a modification of the established procedure of invasive monitoring and cortical resection.
Obtaining the information to perform frequency analysis does not necessarily require any alteration to standard invasive monitoring, however, these data can be used to alter the resection strategy, according to the following four scenarios: (a) HFO analysis may corroborate resection margins based on conventional localization methods; (b) HFO analysis may suggest a more extensive resection is required; (c) HFO analysis may suggest that a less extensive resection may be sufficient; or (d) the widespread presence of HFOs may indicate that a resective procedure is unlikely to accomplish seizure-freedom and therefore invasive intracranial electrodes should be removed without neocortical resection.
For scenario (a), since the use of HFOs does not alter the proposed resection plan, there is essentially no deviation from standard practice, but ethical conflicts may arise nonetheless. It remains important in circumstances where innovative technology is introduced to patient care to recognize the distinction between innovations in technique and innovations in technology. 22 While the technique may be unaltered in this scenario, a novel technology has been introduced. Recognition of this fact is important, as patients may be exposed to harm if the technology For scenarios (b), (c) and (d), where discordance arises between the proposed resection and HFO profiles of the cortex, there is a risk of exposing patients to harm by not sufficiently removing epileptogenic areas, which can fail to achieve a satisfactory seizure outcome or by applying an over-aggressive strategy, which can result in iatrogenic neurological deficits. Germane to their right to autonomy, patients (and parents in the case of children) may choose to sacrifice eloquent brain for a certain likelihood of seizure-freedom. 5 The acceptable risk-to-perceived-benefit ratio, which is in part dictated by the severity of the epilepsy syndrome and the perceived likelihood of seizure-freedom is discussed in informed consent discussions. It is useful when addressing such ethical conflicts to consider whether other technologies are subject to similar ethical dilemmas. Indeed, the problem of extent of resection in the context of limited evidence for a specific localization modality is a pervasive challenge in epilepsy surgery. This is further augmented by the lack of consensus for a standard of care. For instance, a structural MRI may show a lesion, however, resection of this lesion may be insufficient to bestow seizure freedom. Alternatively, a PET scan may demonstrate a large area of hypometabolism, but a smaller resection may be adequate to achieve seizure freedom. Therefore, it is pertinent that the concordance of numerous localization modalities typically correlates with good outcomes. 25 Informed consent discussion and pre-operative planning should, therefore, focus on the multimodality use of these technologies. While HFOs are a seemingly robust marker of epileptogenicity, until more thorough research is conducted, it must be recognized that at present, there is inadequate evidence to suggest that they are less fallible than other localization tools and discordance with other localization modalities should be discussed during the consent process.
The impact of the novel innovation on patient counseling and prognostication is also noteworthy. For example, if the clinician knew that residual cortex expressed HFOs, he/she could counsel the patient regarding risk of seizure recurrence accordingly. Before this is accomplished, the validity of HFOs would need to be better established and greater knowledge regarding their predictive value would need to be ascertained. Clinicians should be aware, however, that with the introduction of these surgical innovations to patient care, the patient encounter itself, not only the surgical procedure, would be affected.
What is the minimum sufficient level of evidence required before acceptance of HFOs as a bona fide surgical adjunct?
Evidence-based medicine has become a major driving force in clinical research and significantly changed clinical practice over the last several decades. Randomized controlled trials (RCTs) specifically are the gold-standard for evaluation of a procedure's efficacy. The importance of adequate evidence for ethical clinical care, is highlighted by the troublesome history of 'innovative' treatments for epilepsy, which included amputation of affected limbs, colectomy and purgation. 26, 27 Despite the importance of evidence in guiding clinical practices, the majority of surgical innovations do not undergo randomized clinical trials; therefore, the standard of 'adequate evidence' is unclear. 28, 29 In fact, authors have previously suggested that ''one should not unnecessarily obstruct surgical innovation by always insisting on orthodox and rigid adherence to the tenets of the prospective randomized double-blind controlled trial''. 30 It is highly unlikely that the use of HFOs to guide neocortical resections will be subject to a formal RCT. For the conduct of such trials, and to ethically randomize patients into treatment cohorts, equipoise must be present between the two treatment arms under consideration. It is uncommon in epilepsy surgery to have true equipoise, as resections are tailored to the individual circumstances of the child. These include preoperative burden of disease, willingness to accept varying degrees of risk incurred by iatrogenic injury to eloquent cortex and considerable heterogeneity in epileptic network size, extent and organization. 5 A methodologically rigorous design may involve a two-stage surgery, whereby a smaller cortical resection is first attempt, followed by a more extensive resection. The former may be defined by traditional localization modalities (scenario b above) or by HFO analysis (scenario c above). If the patient fails to achieve seizurefreedom, a second stage surgery can be planned to remap the area. There are, however, numerous concerns raised by such designs. Firstly, from an ethical perspective, clinicians must question whether to subject the patient to the risks of a two-stage procedure. Furthermore, given the impediment of prolonged uncontrolled seizures, it may be unethical to not perform the most extensive safe resection upfront, particularly if all the epileptogenic tissue is in non-eloquent cortex. Secondly, from an epilepsy perspective, various challenges arise, including the ''running down phenomenon'', whereby seizures may remit after a period of months to years following surgery. 31, 32 This is thought to result following failure to resect the entire epileptogenic zone, where the remaining regions are not sufficient to indefinitely generate seizures autonomously. The running down phenomenon, in combination with unpredictable post-operative epileptic network reorganization would confound timing for a second stage procedure, as well as the conclusions derived from such a study design. The best available evidence for the use of HFOs are small case series, which are limited by factors such as patient selection bias, a potential for lack of generalizability as these studies are typically conducted by single operators at a specific centre (i.e. limited external validity), as well as inadequate or variable follow-up. 33 In a recent position statement pertaining to the regulation of surgical innovations, the Society of University Surgeons suggested that if outcomes of an innovation have not been previously detailed, then a review by a local surgical innovations committee must be conducted, the innovation should be submitted to the national innovations registry and additional informed consent is required of the patient. 34 Alternatively, it has been suggested that appropriate progression to widespread adoption of a novel innovation includes performing observational studies with some degree of standardization of the procedure and an attempt to involve multiple surgeons at different centers. 33 An additional challenge arises from obtaining informed consent for future prospective studies of HFO-guided resections. In their proposed ''Surgical Innovation Ethics Paradigm'', McKneally and Daar propose that patients undergoing innovative procedures must be told that they are free to choose standard care rather than the experimental treatment. 35 This poses an additional challenge to research in this field, as significant heterogeneity exists in the practice of pediatric epilepsy surgery. 36 Discrepancies exist between localization modalities, and procedures such as prevalence of surgery for non-lesional epilepsy cases. Furthermore, the recruitment of patients for such experiments may create conflicts for the treating physicians as both the healthcare provider and clinical investigator, as these responsibilities may carry different and competing obligations. 37, 38 The patients may demonstrate a ''therapeutic misconception'', when they mistake their involvement in research as part of their care. This is particularly important given that families of children with epilepsy are highly motivated to seek novel treatments to mitigate the detrimental effect of seizures. 39 We have previously explored this topic in-depth in other vulnerable patient groups, including those with brain tumors. 40 Finally, in light of obstacles encountered in obtaining high quality epidemiological research, it is important to generate theoretical evidence of the use of HFOs to guide neocortical resections by attempting to understand their pathogenesis and role within broader epileptic networks. Such theoretical underpinnings may serve to legitimize this surgical innovation and provide more evidence to ethically justify its use in clinical populations. For instance, it would be important to understand why and how HFOs spread to distributed cortical areas during seizures 41 and how to differentiate normal from pathological HFO signatures.
Does the implementation of HFO-guided resections affect the distribution of healthcare?
We have previously published that inequity in access to pediatric epilepsy surgery remains a pervasive problem that can stem from variable referral practices and discrepancies in diagnostic tools. 42 For instance, centers utilizing a 1.5 T MR scanner may miss lesions that are conspicuous on a 3 T scanner and therefore, the geographic location of a particular patient may affect their chances of seizure-freedom. Two ethical issues arise from the use of HFOs with respect to the distribution of healthcare: (1) the implementation of HFO-guided resections at specific centers may further contribute to inequities in access to epilepsy surgery; and (2) as novel innovations are almost always more expensive than existing treatments, the use of HFOs may divert resources from more established, and effective alternatives. 23 With regards to the first issue under consideration, it has been clearly outlined that that societies, institutions and governments have an ethical obligation to facilitate equitable access to healthrelated resources. 43 This obligation is, however, also balanced by a responsibility to strive to improve current practices and surgical innovations are one way to improve outcomes for children with medically-intractable epilepsy. Furthermore, given the heterogeneity in practice of epilepsy surgery, the ethical challenge of providing equitable care is not unique to the use of HFOs to guide neocortical resections. Better guidelines are required to guide resource allocation to pre-surgical evaluation of such patients. A related ethical consideration concerns the questionable generalizability of published outcome data in the hands of less experienced centers and the related issue of the surgeon's professional autonomy to make the best decisions for his/her patients based on their individual experience. It is indeed possible that the widespread adoption of a novel surgical procedure may result in worse outcomes in centres with less experience or patient volume, thereby increasing the aforementioned regional disparities. The so-called ''learning curve'' is a well-described challenge in applying surgical innovations to patient care. 44 In recent years, there has been an increased focus on the publication of surgeons' performances, the so-called ''surgeon's report card'', 45, 46 as justified by numerous ethical arguments surrounding professional obligations and patient rights. The extent to which regional reporting of outcomes following application of surgical innovations is required remains an area of ongoing debate.
The second issue is more nuanced and pertains to optimism bias, that is the tendency to overestimate the positive effects of an innovation, thereby contributing both to difficulties in assessing efficacy and overzealous enthusiasm for widespread and premature applications to patient care. 47 The risk, therefore, is that frequency analysis software (which remains an expensive alternative to visual detection of epileptogenic cortex on intracranial EEG) may become adopted as a fad due to its perceived novelty. The questions that would need to be answered before centres divert funding to develop these techniques would not only be whether HFOs analysis leads to improved outcomes, but also how great of an effect is achieved as a result. A marginal outcome benefit may be off-set by the inaccessibility to the technology. This may be analogous to ethical challenges in oncology, where the prescription of expensive pharmaceuticals is debated if the outcome benefit is only marginally superior to less expensive alternatives. 48 
Conclusions
Children with drug-resistant epilepsy represent a vulnerable patient population because of the detrimental effects of uncontrolled seizures on development, cognition, and behavior. Advances in the surgical treatment of intractable epilepsy have contributed to the improvements in seizures outcomes. Innovations in seizure-localization represent a step towards the amelioration of the lives of affected children. Enthusiasm for innovative localization tools, namely electroencephalographic HFOs must however be tempered by evidence-based outcomes, pragmatism and ethical principles. Using an axiological approach, we explored three ethical questions pertaining to the extent to which HFO analysis deviate from established procedures, the level of evidence required prior to widespread adoption and the effects of using these technique on healthcare distribution. It is hoped that the discussion presented herein will contribute to and advance meaningful dialog on this novel technique.
